Literature DB >> 15376198

Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears.

Sukeerat Ruba1, Meike Schoolland, Stephen Allpress, Gregory Sterrett.   

Abstract

BACKGROUND: Little attention has been given to the reasons for failure to detect adenocarcinoma in situ (AIS) of the uterine cervix in Papanicolaou (Pap) smears. In the current study, the authors examined a series of screening or diagnostic errors in cases in which the final histologic diagnosis was either AIS or AIS combined with a high-grade squamous intraepithelial lesion (AIS + HSIL).
METHODS: Smears obtained in the 3 years before histologically proven AIS or AIS + HSIL was diagnosed and within a specified 6-year period (1993-1998) were reviewed and reclassified. All were conventional Pap smears. The smears studied were those with a review diagnosis of possible or definite high-grade epithelial abnormality that initially were reported by a cytotechnologist to be negative (screening error) or that were reported by a pathologist to be negative, unsatisfactory, or indicative of a low-grade epithelial abnormality (diagnostic error). A semiquantitative, blinded assessment of the frequency of cytologic criteria for the diagnosis of AIS was made for smears with erroneous diagnoses compared with a series of smears that yielded true-positive findings.
RESULTS: Sampling errors, which were defined as cases in which smears did not have sufficient evidence for a diagnosis of possible or definite AIS or HSIL on review, accounted for 35.1% and 36% of all smears from patients with a biopsy diagnosis of AIS and patients with a biopsy diagnosis of AIS + HSIL, respectively. With regard to AIS, there were 3 screening errors and 5 diagnostic errors, accounting for 10.4% of 77 smears. Minimal, poorly preserved material was evident in four smears, including three smears with only one sheet of abnormal glandular cells. In four other smears, there was a moderate amount of adequately preserved glandular material, mainly in large sheets, with varying degrees of crowding and hyperchromasia. With regard to AIS + HSIL, there were 6 screening errors and 6 diagnostic errors, accounting for 13.5% of 89 smears. In those smears, there generally was a moderate amount of abnormal material in the form of crowded groups of suboptimally preserved, hyperchromatic squamous cells. Only two of those smears yielded findings of possible abnormal glandular cells. Only 3 of 20 errors occurred in smears that were examined during the last 3 years of the study. In the semiquantitative assessment, smears with erroneous findings were shown to contain far less abnormal material than true-positive smears and to exhibit a corresponding paucity of diagnostic criteria.
CONCLUSIONS: Sampling errors were the main cause of false-negative reports in cases of AIS and AIS + HSIL. The primary factors that contributed to screening or diagnostic errors in AIS were minimal, poorly preserved abnormal material and an overly conservative approach to the assessment of unusual large sheets or aggregates of glandular cells. With regard to AIS + HSIL, most laboratory errors were related to the presence of crowded groups of squamous epithelial cells. There were fewer errors in the last 3 years of the study, raising the possibility of improvement over time.

Entities:  

Mesh:

Year:  2004        PMID: 15376198     DOI: 10.1002/cncr.20600

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls.

Authors:  David C Wilbur
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 2.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

3.  Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Authors:  Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger
Journal:  Int J Cancer       Date:  2019-05-06       Impact factor: 7.316

4.  Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases.

Authors:  Takashi Umezawa; Miyaka Umemori; Ayana Horiguchi; Kouichi Nomura; Hiroyuki Takahashi; Kyosuke Yamada; Kazunori Ochiai; Aikou Okamoto; Masahiro Ikegami; Motoji Sawabe
Journal:  Cytojournal       Date:  2015-04-29       Impact factor: 2.091

5.  Detection of in situ and invasive endocervical adenocarcinoma on ThinPrep Pap Test: Morphologic analysis of false negative cases.

Authors:  Michael Chaump; Edyta C Pirog; Vinicius J A Panico; Alexandre Buckley D Meritens; Kevin Holcomb; Rana Hoda
Journal:  Cytojournal       Date:  2016-12-20       Impact factor: 2.091

Review 6.  Laparoscopic supracervical hysterectomy for benign gynecologic conditions.

Authors:  Beth Hamilton; Stephanie N McClellan; Mark A Rettenmaier; Bram H Goldstein
Journal:  JSLS       Date:  2009 Jan-Mar       Impact factor: 2.172

7.  Mini-laparoscopic hysterectomy for adenocarcinoma in situ of the uterine cervix using interchangeable 5-mm end effectors: a way to cross the line of minimally invasive surgery in gynaecologic oncology.

Authors:  A Galvao; D Goncalves; Morgado Alexandre; H Ferreira
Journal:  Facts Views Vis Obgyn       Date:  2017-09

8.  Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis.

Authors:  Rachel D Conrad; Angela H Liu; Nicolas Wentzensen; Roy R Zhang; S Terence Dunn; Sophia S Wang; Mark Schiffman; Michael A Gold; Joan L Walker; Rosemary E Zuna
Journal:  Cancer Cytopathol       Date:  2018-10-23       Impact factor: 5.284

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.